Literature DB >> 16760517

Verified bites by yellow sac spiders (genus Cheiracanthium) in the United States and Australia: where is the necrosis?

Richard S Vetter1, Geoffrey K Isbister, Sean P Bush, Lisa J Boutin.   

Abstract

Spiders of the genus Cheiracanthium are frequently reported in review articles and medical references to be a definitive cause of dermonecrosis or necrotic arachnidism in humans. We provide 20 cases of verified bites by Cheiracanthium spiders from the United States and Australia, none with necrosis. A review of the international literature on 39 verified Cheiracanthium bites found only one case of mild necrosis in the European species C. punctorium. The basis for the suggestion that this spider genus causes dermonecrosis seems to be mostly inference from venom experiments in rabbits and guinea pigs, circumstantial spider involvement in human skin lesions, and repetitive citation of non-definitive reports in the medical literature. We discuss factors that lead to the erroneous elevation of virtually innocuous spiders to that of significant medical concern, which is a recurring problem in the medical community.

Entities:  

Mesh:

Year:  2006        PMID: 16760517

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Novel class of spider toxin: active principle from the yellow sac spider Cheiracanthium punctorium venom is a unique two-domain polypeptide.

Authors:  Alexander A Vassilevski; Irina M Fedorova; Ekaterina E Maleeva; Yuliya V Korolkova; Svetlana S Efimova; Olga V Samsonova; Ludmila V Schagina; Alexei V Feofanov; Lev G Magazanik; Eugene V Grishin
Journal:  J Biol Chem       Date:  2010-07-24       Impact factor: 5.157

2.  An extensive case of dermonecrotic arachnidism.

Authors:  Sherrie J Divito; Justin M Haught; Joseph C English; Laura K Ferris
Journal:  J Clin Aesthet Dermatol       Date:  2009-09

Review 3.  Yellow sac spider (Cheiracanthium punctorium) bites in Slovenia: case series and review.

Authors:  Tanja Varl; Damjan Grenc; Rok Kostanjšek; Miran Brvar
Journal:  Wien Klin Wochenschr       Date:  2017-05-24       Impact factor: 1.704

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.